Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.